|
Wyeth Receives Approvable Letter From FDA For Pristiq (Desvenlafaxine Succinate) For The Treatment.. |
|
|
|
|
Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that the Company has received an approvable letter from the U.S. Food and Drug Administration (FDA) for Pristiq(TM) (desvenlafaxine succinate), a serotonin-norepinephrine reuptake inhibitor (SNRI) studied as a treatment for adult patients with major depressive disorder (MDD). The letter was received January 22. [click link for full article] |
|
Read more...
|
|
|
New Drug Therapy To Combat Graft-vs.-Host Disease In Stem-Cell Patients Shows Significant Reduction. |
|
|
|
|
Gastrointestinal graft-vs.-host disease is a common and potentially deadly side effect for patients who undergo an allogeneic stem-cell transplant to treat certain blood cancers. [click link for full article] |
|
Read more...
|
|
|
Renovis Restructures To Focus On Advancing Its Neurological And Inflammatory Disease Programs Into.. |
|
|
|
|
Renovis, Inc. (Nasdaq: RNVS) today announced that it has reduced its workforce by approximately 40 percent of its positions as part of a restructuring plan intended to significantly reduce spending while maintaining the research and development capabilities needed to advance the Company's late-stage preclinical drug discovery programs. [click link for full article] |
|
Read more...
|
|
|
New Drug Therapy To Combat Graft-vs.-Host Disease In Stem-Cell Patients Shows Significant Reduction. |
|
|
|
|
Gastrointestinal graft-vs.-host disease is a common and potentially deadly side effect for patients who undergo an allogeneic stem-cell transplant to treat certain blood cancers. [click link for full article] |
|
Read more...
|
|
|
Renovis Restructures To Focus On Advancing Its Neurological And Inflammatory Disease Programs Into.. |
|
|
|
|
Renovis, Inc. (Nasdaq: RNVS) today announced that it has reduced its workforce by approximately 40 percent of its positions as part of a restructuring plan intended to significantly reduce spending while maintaining the research and development capabilities needed to advance the Company's late-stage preclinical drug discovery programs. [click link for full article] |
|
Read more...
|
|
|
|
<< Start < Prev 7121 7122 7123 7124 7125 7126 7127 7128 7129 7130 Next > End >>
|
| Results 64126 - 64134 of 70931 |
